Neurology Department, Xuan Wu Hospital, Capital Medical University, Beijing, China.
Neurology Department, Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, China.
Braz J Psychiatry. 2021 May-Jun;43(3):306-313. doi: 10.1590/1516-4446-2020-0945.
To evaluate the efficacy and safety of Morinda officinalis oligosaccharide (MOO) capsules for depressive disorder.
Eight electronic databases were searched for relevant studies from inception to April 19, 2020. Randomized controlled trials comparing MOO capsules with antidepressants were included. Data analysis was conducted using Review Manager 5.3 software. The risk of bias was assessed using the Cochrane Risk of Bias Tool, and the quality of the studies was evaluated by two researchers using the Grading of Recommendation, Assessment, Development and Evaluations (GRADE) software.
Seven studies involving 1,384 participants were included in this study. The effect of MOO capsules for moderate depressive disorder was not different from that of antidepressants (risk ratio [RR] = 0.99, 95%CI 0.92-1.06). Regarding adverse events, no significant difference was found between MOO capsules and antidepressants (RR = 0.84, 95%CI 0.65-1.07). In addition, the quality of evidence related to these adverse events was rated as low.
This systematic review suggests that the efficacy of MOO capsules in the treatment of mild to moderate depression is not inferior to that of conventional antidepressants, which may provide a new direction for clinical alternative selection of antidepressants. However, more high-quality research and detailed assessments are needed.
评价巴戟天寡糖胶囊治疗抑郁症的疗效和安全性。
检索建库至 2020 年 4 月 19 日的 8 个电子数据库，纳入比较巴戟天寡糖胶囊与抗抑郁药的随机对照试验。采用 Review Manager 5.3 软件进行数据分析。采用 Cochrane 偏倚风险工具评估偏倚风险，使用 GRADE 软件由 2 位研究者独立评价研究质量。
本研究纳入 7 项研究，共 1384 名参与者。巴戟天寡糖胶囊治疗轻中度抑郁症的效果与抗抑郁药无差异（风险比[RR] = 0.99，95%CI 0.92-1.06）。关于不良反应，巴戟天寡糖胶囊与抗抑郁药之间无显著差异（RR = 0.84，95%CI 0.65-1.07）。此外，这些不良反应相关证据的质量被评为低。
本系统评价提示，巴戟天寡糖胶囊治疗轻中度抑郁症的疗效不劣于传统抗抑郁药，这可能为临床抗抑郁药的选择提供新的方向。但需要更多高质量的研究和详细评估。
